

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

217836US0PCT

U.S. APPLICATION NO. (IF KNOWN; SEE 37 CFR

10/030114

INTERNATIONAL APPLICATION NO.
PCT/EP00/07184INTERNATIONAL FILING DATE
26 July 2000PRIORITY DATE CLAIMED
30 July 1999

TITLE OF INVENTION

2-AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF GLAUCOMA

APPLICANT(S) FOR DO/EO/US

BONGRANI Stefano et al.


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:


13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Form PTO-1449
Request for Priority

U.S. APPLICATION NO. 10/030114		INTERNATIONAL APPLICATION NO. PCT/EP00/07184		ATTORNEY'S DOCKET NUMBER 217836US0PCT	
24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$890.00				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$130.00	
CLAIMS		NUMBER FILED		NUMBER EXTRA	
Total claims		5 - 20 =		0	
Independent claims		2 - 3 =		0	
Multiple Dependent Claims (check if applicable).		<input type="checkbox"/>		RATE	
TOTAL OF ABOVE CALCULATIONS =				\$1,020.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,020.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,020.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				\$0.00	
TOTAL FEES ENCLOSED =				\$1,020.00	
				Amount to be: refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$1,020.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. in the amount of to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0030 A duplicate copy of this sheet is enclosed.					
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Surinder Sachar Registration No. 34,423					
					
22850					
SIGNATURE					
Norman F. Oblon					
NAME					
24,618					
REGISTRATION NUMBER					
Jan 23 2002					
DATE					

2-AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF GLAUCOMA

The present invention relates to the use of racemic or optically active compounds represented by formula I and the salts thereof



wherein R is H or CH₃,

for the preparation of pharmaceutical compositions for the therapy of ophtalmic disorders.

More particularly, the invention relates to the use of (±)-(R,S)-5,6-diisobutyroyloxy-2-methylamino-tetralin or its (-)-(S)- enantiomer in the preparation of ophthalmic formulations for the treatment of glaucoma.

Glaucoma is an ophthalmic disorder characterized by increased intraocular pressure which causes excavation and degeneration of the optic disc. Notwithstanding the therapeutical progresses attained, glaucoma, whose etiology has not yet been completely clarified, is one of the main causes of irreversible blindness.

Three types of glaucoma are known: primary, secondary and congenital glaucoma. Primary glaucoma is, in turn, classified in acute congestive or angle-closure glaucoma and simple chronic or open-angle glaucoma. The high intraocular pressure (IOP) is due to insufficient outflow of the aqueous humour from the eye anterior chamber.

Therefore, the symptomatic therapy usually aims at decreasing the intraocular pressure, which can be attained via three mechanisms: i) increasing of the outflow of aqueous humor by use of direct parasympathomimetic or cholinesterase inhibitors; ii) dehydration of the eye bulbs by use of osmotic agents such as urea or mannitol; iii) reduction in the aqueous humor production by the ciliated epithelium: a number of medicaments, such as carbonic anhydrase inhibitors and β -blockers, act according to this mechanism.

The medicaments of the various classes cited above can be administered either alone or in combinations thereof.

Sympathomimetics have been widely used in the past, mainly in the treatment of open-angle glaucoma. These drugs act either through direct stimulation of adrenergic receptors or through release of catecholamines from the synaptic vesicles of the adrenergic nerve terminals. They differ both in their selectivity towards specific receptors and in the intensity of the adrenergic responses they give rise to. Depending on the type of receptors preferably involved, they can act either by promoting the outflow of aqueous humor or by decreasing its production. However, such drugs induce a number of side effects mainly connected with their aspecificity, therefore the use of such medicaments as adrenaline or its corresponding pro-drug dipivefrin is restricted to a combination therapy in patients in which β -blockers are contraindicated. In order to decrease the onset of side effects, research has been focused on drugs with higher selectivity, particularly towards pre-synaptic α_2 -adrenoceptors. α_2 -Agonists act both by promoting the outflow of aqueous humor and by decreasing its production. Two Clonidine analogues belonging to this pharmacological class, namely Brimonidine and

Apraclonidine, have recently been introduced in therapy. The search for drugs for the treatment of glaucoma is also directed to dopamine analogues for their capability of stimulating α -adrenoceptors in addition to the dopaminergic ones. By virtue of this dual action, the decrease in intraocular pressure can take place through a plurality of mechanisms of action. In many experimental studies some DA₂-agonists were found particularly active; since they induce inhibition of catecholamines release in the eye, they can be functionally considered as indirectly acting β -blockers. Among dopaminergic medicaments, a number of aminotetralin derivatives have been the object of several studies and Patent applications.

Burke J et al. (J. Auton. Pharmac. 4, 185-192, 1984) report that 6,7-dihydroxy-2-aminotetralin and N,N-dimethyl-6,7-dihydroxy-2-aminotetralin, administered as ophthalmic drops, gives rise to eye hypotension in the rabbit. A subsequent study, carried out on the same experimental model by Thörig L et al. (Ophthalmic Res. 17, 362-372, 1985) showed that N,N-dimethyl-5,6-dihydroxy-2-aminotetralin (M-7) is active as well in reducing intraocular pressure but induces eye irritation already at a concentration of 0.1%. In a general way catechol derivatives are characterized by inherent stability problems which could adversely affect their successful pharmaceutical employment. Moreover the partition coefficient ($\log P_{app}$) of 2-amminotetralins with the catechol group free is usually not optimal for ocular absorption (Schoenwald R D et al. J. Pharm. Sci. 72, 1266-1272, 1983 and J. Pharm. Sci. 67, 787-789, 1978).

US 4,588,747 in the name of Synthelabo claims the use of N,N-propyl-6-hydroxy-formylamino-2 aminotetralins.

US 4,657,925 in the name of Nelson R & D claims the use

WO 01/08667

PCT/EP00/07184

of variously substituted N-alkyl, N-arylalkyl-2-aminotetralins, acting on DA₂ receptors. More particularly, the use of 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin is claimed. Said derivative however, although exerting a long-lasting action, can also induce eye irritation.

US 4,722,933, in the name of Alcon, claims the use of 5,6-acyloxyloxy-1-hydroxy-2-aminotetralin derivatives lacking side effects on the cardiovascular system.

US 5,382,596, EP 163458, US 5,430,056, EP 627407, US 5,140,040, US 5,086,074 claim other aminotetralin derivatives utilizable in a number of pathologies, including glaucoma, which could benefit from a treatment based on dopaminergic medicaments. Said documents report no data supporting the effectiveness in the treatment of said disease.

None of these compounds has to-date been introduced in therapy. Therefore, a need exists for aminotetralin derivatives for the treatment of glaucoma which provides for potent control of elevated IOP without causing significant side effects, especially on the cardiovascular system. In particular, a need exists for derivatives with good local tolerability and topical bioavailability, soluble as well stable in aqueous medium and which do not show tolerance upon prolonged administration.

OBJECT OF THE INVENTION

(±) - (R,S) - 5,6-diisobutyryloxy-2-methylaminotetralin, (from now on referred to as CHF 1035), was first disclosed in GB 2,123,410 among a series of potentially antibronchospastic aminotetralin derivatives; afterwards the use of said compound in the treatment of cardiac disorders, particularly congestive heart failure, was claimed.

It has now been found that CHF 1035 can be effectively

WO 01/08667

PCT/EP00/07184

used in the treatment of glaucoma through the topical administration.

Studies carried out in normotensive rabbits as well as in rabbits with water-increased IOP showed that CHF 1035 in the form of ophthalmic drops significantly decreases, after single administration, the intraocular pressure.

As regards to the study in normotensive rabbits, advantageously, compared to brimonidine, no significant IOP decrease was observed in the untreated eye, indicating that very little or no systemic absorption occurred. In comparison to said reference compound, CHF 1035 exhibits a less rapid onset of action, but a longer duration of action.

Further results prove that CHF 1035 induces a persistent decrease in IOP after repeated administrations.

The 5,6-diisobutyroyloxy-2-methylamino-tetralin derivative, compared with the compound with the free catechol group at the 5,6 position or with other similar compounds (M-7), has better characteristics in terms of chemical stability and ocular bioavailability, as proved by the higher partition coefficient n-octanol/buffer pH 7.4 ($\log P_{app} = 0.75$ vs. -0.9). The better chemical stability, makes the handling of the starting material easier and also allows to prepare solutions for the ophthalmic use with pH nearer to the physiological values and therefore better tolerated.

Furthermore, it has surprisingly been found that, contrary to what stated in the prior art (Järvinen T et al. Adv. Drug Deliv. Rev. 1996, 19, 203-224), the protection of the catechol group through formation of the corresponding diisobutyroyloxy derivative, besides improving corneal permeability, also increases the ocular tolerability of the drugs. The medicament is indeed well tolerated up to 5%

concentration, causing neither irritation symptoms such as redness and blinking, nor other undesired side effects. Chetoni P et al. Int. J. Pharm. 105, 147- 155, 1994 report that in case of, for example, albuterol, the synthesis of
5 the corresponding esterified pro-drug, although increasing effectiveness, does not prevent its irritant effects. Dipivefrin, which has been introduced on the market as a pro-drug of adrenaline in the form of dipivaloyl ester, gives rise to side effects such as pain in the eye and in
10 the superciliary arch as well as corneal vascularization and opacification during long-term use. (Salminen L et al. J. Ocul. Pharmacol. Ther. 11, 37-40, 1995). The in vivo use of the prodrugs of pilocarpine is associated with ocular irritation (Saarinen-Savolainen P et al. Int. J. Pharm.
15 133, 171-178, 1996; Suhonen P et al. Int. J. Pharm. 127, 85-94, 1996).

For its favorable characteristics, CHF 1035 can be advantageously used for the preparation of compositions for the ophthalmic use in the therapy of glaucoma. Even more
20 preferred is the use of the corresponding (-)-(S) enantiomer which is about twice as much selective towards the α_2 and DA_2 receptors than the racemate.

The present invention, besides CHF 1035, also includes the analogous derivative without the methyl group on the
25 amino group. The compounds of the invention can be used in the form of salts with inorganic acids, such as hydrochloride and hydrobromide, or with organic acids such as acetate, tartrate and citrate.

The amount of active ingredient to be used will vary
30 with the age of the patient and the severity of the glaucoma.

Generally, the concentration of the active ingredient will range from 0.001 to 5%, preferably between 0.01 and

1.0%.

For the ocular administration, the compounds can be formulated as aqueous solution or in the form of ointments, creams or gels, by using the conventional additives and excipients.

Preferred carriers for the compounds of the invention are those consisting of a sterile isotonic aqueous solution, for the administration in the form of ophthalmic drops, containing viscosity-increasing agents such as hydroxypropylmethylcellulose, stabilizing agents such as EDTA or sodium bisulfite, preservatives such as benzalkonium chloride or chlorobutanol.

Advantageously, the pH of the ophthalmic composition will be adjusted between 3.0 to 7.5 by using conventional buffering agents such as borates, carbonates or phosphates. Preferably it will be adjusted between 4.0 and 5.0 avoiding buffers in order to manipulate the physiological environment of precorneal area as little as possible.

The invention is illustrated in detail by the following examples.

Example 1 - Determination of apparent partition coefficient

The apparent partition coefficients ($\log P_{app}$) of CHF 1035 were determined from the distribution of the compound between 1-octanol and phosphate buffer solution (50 mM; pH 1.4, 5.5, 6.5 and 7.4). The phosphate buffer solution and 1-octanol were saturated with each other, prior to partition study, by shaking vigorously for 24 h. A known concentration of CHF 1035 in the phosphate buffer solution was shaken 60 minutes with suitable volume of saturated 1-octanol. After shaking, the phases were separated by centrifugation, and the concentrations of CHF 1035 in the buffer phase were determined by HPLC before and after partitioning. The results expressed as a mean \pm SD

(standard deviation) are reported in Table 1.

Table 1. Apparent partition coefficient ($\log P_{app}$, mean \pm SD, $n = 3$) of CHF 1035.

5	pH of buffer solution	$\log P_{app}$ (mean \pm SD, $n = 3$)
	4.5	0.17 ± 0.02
	5.5	0.17 ± 0.01
	6.5	0.20 ± 0.08
10	7.4	0.75 ± 0.02

CHF 1035 is a base with $pK_a = 9.4$, so its $\log P_{app}$ value increases with increased pH. The higher apparent partition
15 coefficient would be more favorable for ophthalmic absorption. However, an acid aqueous solution should be used as a vehicle for eyedrop administration due to the better chemical stability of CHF 1035 in such pH range. The theoretical $\log P_{app}$ of the corresponding not esterified
20 derivative turned out to be -0.9 at pH 7.4.

Example 2 - Intraocular pressure (IOP) studies after single dose in normotensive rabbits.

Water (pH 4.5, made isotonic with sodium chloride), was selected as vehicle for the IOP-studies. Buffer solution
25 was not used in order to manipulate the physiological environment of precorneal area as little as possible. pH 4.5 was selected to confer a good stability to CHF 1035.

Five concentrations (0.01, 0.05, 0.2, 0.5 and 1.0 % w/v) of CHF 1035 were studied. Brimonidine (0.2 % w/v) was
30 used as a positive, and vehicle (water pH 4.5) as a negative control.

The experimental animals used were normotensive Dutch Belted rabbits of either gender ($n = 6$). A single drop (25 μ l) of the test solution was instilled unilaterally into

the left eye (treated eye). IOP of the rabbits (treated and untreated eyes) was measured at 1 and 0 h before, and at 0.5, 1, 2, 3, 4, 5, 6 and 7 h after topical eyedrop administration. IOP at the time of eyedrop administration (0 h) was used as a baseline value. IOP was measured using a BioRad Pneumatonometer. More detailed description of the IOP measurement procedure can be found in Pharm. Res. 14, 1738-1743, 1997 and Curr. Eye Res. 14, 791-797, 1995. All the studies were set up using a randomized crossover design. At least 72 h of wash-out time was allowed for each rabbit between dosings. The irritation caused by an instilled eyedrop were evaluated by recording the extent of eyelid closure after topical eyedrop administration.

The effects expressed as change from baseline (mmHg) are reported in Table 2 and 3 as mean \pm SEM (standard error of mean).

CHF 1035 decreases significantly the IOP in the treated eye after topical administration into normotensive rabbits. However, no significant IOP decrease is observed in the untreated eye, which is considered to be a benefit. The minor IOP effects in untreated eye may mean minor systemic absorption and decreased risk for serious systemic side-effects.

CHF 1035 shows a late onset of action which may be caused by its prodrug-nature. The maximum decrease in IOP occurs between 5 and 6 h with doses between 0.2 % and 1.0 %. In cases of smaller doses (i.e., doses 0.01 % and 0.05 %), the maximum decrease in IOP tends to be earlier. The prodrug-nature may also prolong the duration of action of CHF 1035.

Topical administration (single dose) of CHF 1035 did not cause significant eye irritation in rabbits: no eyelid closure was observed after topical administration (25 μ l) of 0.5%, 0.2%, 0.05% and 0.01% CHF 1035 solution.

WO 01/08667

PCT/EP00/07184

CHF 1035 also turned out to be more effective in decreasing IOP than brimonidine, and has longer duration of action than brimonidine.

5 No significant IOP changes was observed after vehicle administration: the IOP change was between -1.1 and 1.4 mmHg, and between 0.3 and 1.5 mmHg in the treated and in the untreated eye, respectively.

Table 2. Intraocular pressure (IOP) changes (mean mmHg \pm SEM) in the treated eye of normotensive rabbits (n = 6) after unilateral administration of test solution.

DOSE (% w/v)	TIME (min)								
	0	30	60	120	180	240	300	360	420
water *	0.0 ± 0.0	0.7 ± 0.4	-0.9 ± 0.4	-0.3 ± 0.6	0.0 ± 0.6	-0.2 ± 0.5	0.0 ± 0.7	-0.4 ± 0.9	0.6 ± 0.9
1.0 % CHF	0.0 ± 0.0	1.3 ± 0.9	0.4 ± 1.0	0.1 ± 0.9	-3.2 ± 1.8	-4.9 ± 1.5	-5.8 ± 1.6	-6.6 ± 1.6	-5.3 ± 1.5
0.5 % CHF	0.0 ± 0.0	1.8 ± 0.6	1.2 ± 0.7	0.1 ± 0.7	-5.0 ± 1.2	-5.6 ± 0.6	-7.9 ± 0.9	-6.9 ± 0.8	-7.0 ± 0.8
0.2 % CHF	0.0 ± 0.0	0.8 ± 0.9	-0.4 ± 1.1	-2.1 ± 0.7	-6.0 ± 0.9	-6.3 ± 1.0	-7.6 ± 1.5	-6.9 ± 1.0	-5.7 ± 1.1
0.05 % CHF	0.0 ± 0.0	-0.4 ± 0.5	-3.3 ± 0.4	-6.5 ± 0.9	-6.3 ± 0.9	-6.7 ± 0.8	-6.4 ± 0.8	-5.5 ± 0.7	-4.3 ± 0.5
0.01 % CHF	0.0 ± 0.0	-1.9 ± 0.9	-4.2 ± 1.1	-5.3 ± 0.7	-5.0 ± 1.0	-4.5 ± 1.3	-4.3 ± 0.9	-2.6 ± 0.6	-1.3 ± 0.8
0.2 % Brim.	0.0 ± 0.0	-2.7 ± 0.9	-7.8 ± 0.9	-6.2 ± 1.4	-3.9 ± 0.8	-3.4 ± 0.7	-2.4 ± 0.7	-0.4 ± 0.6	0.2 ± 0.3

* = n equals 12 (2 x 6) instead of 6

CHF = CHF 1035 HCl

Brim. = Brimonidine

Table 3. Intraocular pressure (IOP) changes (mean mmHg \pm SEM) in the untreated eye of normotensive rabbits (n = 6) after unilateral administration of test solution.

DOSE (% w/v)	TIME (min)								
	0	30	60	120	180	240	300	360	420
water *	0.0 ± 0.0	0.3 ± 0.5	-0.4 ± 0.3	0.0 ± 0.5	-0.2 ± 0.4	-0.4 ± 0.4	-0.7 ± 0.7	0.3 ± 0.8	0.9 ± 0.4
1.0 % CHF	0.0 ± 0.0	2.2 ± 0.9	1.2 ± 1.2	1.0 ± 0.8	-2.5 ± 1.3	-1.8 ± 0.6	-0.7 ± 0.8	-0.2 ± 1.1	-0.9 ± 1.0
0.5 % CHF	0.0 ± 0.0	2.9 ± 0.8	2.4 ± 0.7	1.4 ± 0.4	0.0 ± 0.5	-0.2 ± 0.7	-0.9 ± 0.4	-0.7 ± 0.6	-0.2 ± 0.3
0.2 % CHF	0.0 ± 0.0	1.0 ± 0.8	0.5 ± 1.2	0.0 ± 0.9	-1.5 ± 1.2	-1.6 ± 1.1	-1.1 ± 1.1	-0.7 ± 1.0	0.0 ± 0.8
0.05 % CHF	0.0 ± 0.0	0.0 ± 0.6	0.1 ± 0.7	-1.5 ± 0.8	-0.4 ± 1.0	-1.0 ± 0.4	-1.9 ± 0.9	-0.6 ± 1.2	0.3 ± 0.7
0.01 % CHF	0.0 ± 0.0	-1.0 ± 1.1	-1.9 ± 1.2	-1.6 ± 1.0	-0.5 ± 0.7	-1.4 ± 0.7	-1.7 ± 0.4	0.0 ± 0.6	0.4 ± 0.7
0.2 % Brim.	0.0 ± 0.0	-3.2 ± 1.2	-8.7 ± 0.8	-3.3 ± 1.3	-1.7 ± 0.9	-2.1 ± 1.0	-0.6 ± 0.9	0.1 ± 0.6	0.0 ± 0.6

* = n equals 12 (2 x 6) instead of 6

CHF = CHF 1035 HCl

Brim. = Brimonidine

Example 3 - Intraocular pressure (IOP) studies after single dose in rabbits with water-increased IOP.

A study versus placebo was carried out in 20 New-Zealand albino rabbits to evaluate the effects of CHF 1035 after single administration. Basal intraocular pressure (IOP) was measured in anaesthetized rabbits in both eyes. Each eye received two drops of physiological solution containing 5% of the drug. Control animals received only physiological solution. After one hour, the animals were administered by oral route with a total amount of 200 ml of distilled water. IOP increased within about one hour and normalized after about 3 hours. As no differences in IOP were observed between the two eyes, the respective tonometric curves were superimposed. IOP measurements were carried out by using a Goldman tonometer and were repeated one hour after the administration of water.

Figure 1 shows the effect of CHF 1035 on rabbit intraocular pressure (IOP) after water loading. Values are expressed as mean ($SE^1 = 1.6-2.7$). The total number of eyes per group is in brackets.

It can be appreciated that the animals pre-treated with CHF 1035 show an IOP value significantly lower than control animals.

¹ Standard error

Example 4 - Intraocular pressure (IOP) studies after repeated administration in rabbits with water-increased IOP.

The effectiveness of CHF 1035 after repeated administration was tested in a study versus placebo, in 20 New-Zealand albino rabbits. In order to induce a chronic increase of the IOP, each animal was intraocularly injected with 0.5 mg/day of α -chymotrypsin for five days. Starting from the first day of treatment, two drops of physiological

saline containing 5% of the drug were instilled in each eye every 6 hours. The control animals only received physiological saline.

5 The IOP measurement was performed as described in example 1, before the injection and subsequently every day until the 10th day.

Figure 2 reports the effect of CHF 1035 on rabbit IOP after α -chymotrypsin injection. Values are reported as mean (SE = 1.2 -2.6; n = 20 per group).

10 IOP values are similar before the injection of α -chymotrypsin. However, the animals treated with CHF 1035 showed significantly lower IOP than animals treated with placebo. Moreover, the medicament turned out to be well tolerated during the whole cycle of treatment and induced
15 no eye irritation and/or discomfort.

WO 01/08667


PCT/EP00/07184

CLAIMS

1. The use of compounds of formula I, their enantiomers and salts thereof:

5

10



15 wherein R is H or CH₃,
for the preparation of pharmaceutical compositions for the
therapy of glaucoma.

2. The use according to claim 1, of the compound of
formula I in which R is methyl.

20 3. The use according to claim 2 in which the compound of
formula I is (-)-(S)-5,6-diisobutyroyloxy-2-methylamino-
tetralin.

4. Compositions for the ophthalmic use in the treatment
of glaucoma, containing the compounds of formula I in
25 combination with suitable excipients.

5. Pharmaceutical compositions according to claim 4
characterized by a concentration ranging from 0.001 to 5%,
preferably between 0.01% and 1%.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/08667 A3

(51) International Patent Classification⁷: **A61K 31/216**,
A61P 27/06

(21) International Application Number: PCT/EP00/07184

(22) International Filing Date: 26 July 2000 (26.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI99A001713 30 July 1999 (30.07.1999) IT

(71) Applicant (for all designated States except US): **CHIESI FARMACEUTICI S.P.A.** [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BONGRANI, Stefano** [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). **RAZZETTI, Roberta** [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). **CHIESI, Paolo** [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).

(74) Agents: **MINOJA, Fabrizio** et al.; Bianchetti Bracco Minoja SRL, Via Rossini, 8, I-20122 Milano (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


— With international search report.

(88) Date of publication of the international search report:

7 June 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF GLAUCOMA




(I)

(57) Abstract: The use of racemic or optically active compounds represented by formula (I) and the salts thereof wherein R is H or CH₃ for the preparation of pharmaceutical compositions for the therapy of ophthalmic disorders.

WO 01/08667 A3

1/2

FIG. 1




CNT = control values before !carico idrico (the values of the two groups were combined).

SAL = animals treated with physiological saline.

CHF = animals treated with CHF 1035.

* Significant difference compared with the SAL group, $p < 0.05$ (two-way ANOVA).

2/2
FIG. 2



CNT = control values.

CHF = animals treated with CHF 1035.

* Significant difference compared with the control group, $p < 0.05$ (two-way ANOVA).

Declaration, Power Of Attorney and Petition *glaucoma*

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

2-aminotetralin derivatives for the therapy of glaucoma

the specification of which

☐ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____.

☒ was filed as PCT international application

Number PCT/EP00/07184

on 26.07.2000,

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
<u>MI99A001713</u>	<u>Italy</u>	<u>30.07.1999</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

We (I) hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status (pending, patented, abandoned)
_____	_____	_____
_____	_____	_____
_____	_____	_____

And we (I) hereby appoint: Norman F. Oblon, Reg. No. 24,618; Marvin J. Spivak, Reg. No. 24,913; C. Irvin McClelland, Reg. No. 21,124; Gregory J. Maier, Reg. No. 25,599; Arthur I. Neustadt, Reg. No. 24,854; Richard D. Kelly, Reg. No. 27,757; James D. Hamilton, Reg. No. 28,421; Eckhard H. Kuesters, Reg. No. 28,870; Robert T. Pous, Reg. No. 29,099; Charles L. Gholz, Reg. No. 26,395; Vincent J. Sunderdick, Reg. No. 29,004; William E. Beaumont, Reg. No. 30,996; Robert F. Gnuse, Reg. No. 27,295; Jean-Paul Lavalleye, Reg. No. 31,451; Stephen G. Baxter, Reg. No. 32,884; Robert W. Hahl, Reg. No. 33,893; Richard L. Treanor, Reg. No. 36,379; Steven P. Weihrouch, Reg. No. 32,829; John T. Goolkasian, Reg. No. 26,142; Richard L. Chinn, Reg. No. 34,305; Steven E. Lipman, Reg. No. 30,011; Carl E. Schlier, Reg. No. 34,426; James J. Kulbaski, Reg. No. 34,648; Richard A. Neifeld, Reg. No. 35,299; J. Derek Mason, Reg. No. 35,270; Surinder Sachar, Reg. No. 34,423; Christina M. Gadiano, Reg. No. 37,628; Jeffrey B. McIntyre, Reg. No. 36,867; Paul E. Rauch, Reg. No. 38,591; William T. Enos, Reg. No. 33,128; and Michael E. McCabe, Jr., Reg. No. 37,182; our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1-50 BONGRANI Stefano
Stefano Bongrani
NAME OF FIRST SOLE INVENTOR

Residence: Via Palermo, 26/A
PARMA, Italy ITX

Signature of Inventor

Citizen of: Italy

Post Office Address: same as above

23.01.2002
Date

2-00
RAZZETTI Roberta
NAME OF SECOND JOINT INVENTOR

Roberta Razzetti
Signature of Inventor

23.01.2002
Date

3-00
CHIESI Paolo
NAME OF THIRD JOINT INVENTOR

Chiesi
Signature of Inventor

23.01.2002
Date

NAME OF FOURTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF FIFTH JOINT INVENTOR

Signature of Inventor

Date

Residence: Via Palermo, 26/A

PARMA, Italy FTX

Citizen of: Italy

Post Office Address: same as above

Residence: Via Palermo, 26/A

PARMA, Italy FTX

Citizen of: Italy

Post Office Address: same as above

Residence: _____

Citizen of: _____

Post Office Address: _____

Residence: _____

Citizen of: _____

Post Office Address: _____